Experimental cell therapy tested for serious eye inflammation
NCT ID NCT07427628
Summary
This early-stage study is testing a new cell therapy called TRX103 for adults with active non-infectious uveitis, a serious inflammatory eye disease. Researchers will give a single infusion to up to 18 participants and monitor them for one year to check safety and see if it helps control inflammation and preserve vision. This is the first time this therapy is being tested specifically for uveitis.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON INFECTIOUS UVEITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Byers Eye Institute
Palo Alto, California, 94303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.